legislation: 104-s-2051
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| bill_id | congress | bill_type | bill_number | title | policy_area | introduced_date | latest_action_date | latest_action_text | origin_chamber | sponsor_name | sponsor_state | sponsor_party | sponsor_bioguide_id | cosponsor_count | summary_text | update_date | url |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104-s-2051 | 104 | s | 2051 | Pharmacotherapy Development Act of 1996 | Health | 1996-09-03 | 1996-09-03 | Read twice and referred to the Committee on Labor and Human Resources. | Senate | Sen. Biden, Joseph R., Jr. [D-DE] | DE | D | B000444 | 0 | TABLE OF CONTENTS: Title I: Development of Drugs for the Treatment of Addictions to Illegal Drugs Title II: Development, Manufacture, and Procurement of Drugs for the Addiction (sic) of Cocaine and Heroin Addictions Pharmacotherapy Development Act of 1996 - Title I: Development of Drugs for the Treatment of Addictions to Illegal Drugs - Amends the Federal Food, Drug, and Cosmetic Act to add references to drugs for the treatment of addiction to illegal drugs to provisions relating to drugs for rare diseases or conditions, allowing exclusive approval, certification, or licensure, subject to exception. Requires that the sponsor of such a treatment drug be encouraged to design open protocols. Title II: Development, Manufacture, and Procurement of Drugs for the Addiction (sic) of Cocaine and Heroin Addictions - Requires that the Institute of Medicine of the National Academy of Sciences establish criteria for an acceptable drug for the treatment of addiction to cocaine and an acceptable drug for the treatment of addiction to heroin. Allows the patent owner of a drug to treat cocaine or heroin addiction to apply to the Secretary of Health and Human Services to sell the patent rights to, or make an exclusive licensing agreement with, the Secretary. Sets the purchase amount at $100 million for the cocaine treatment drug and $50 million for the heroin treatment drug. Directs the Secretary, after the sale or licensing, to develop a manufacturing and distribution plan. Authorizes appropriations. | 2025-08-21T20:16:40Z |